Report Description Table of Contents Toxoplasmosis Treatment Market: Congenital and Ocular Care Sustain Therapeutic Demand The Global Toxoplasmosis Treatment Market was valued at USD 675.47 million in 2025 and is projected to reach USD 922.30 million by 2032, expanding at a CAGR of 4.55% during 2026–2032. Toxoplasmosis Treatment Market covers pharmaceutical therapies used to manage infections caused by Toxoplasma gondii, particularly in patients with active, severe, ocular, congenital, or immunocompromised disease. The addressable toxoplasmosis treatment burden remains substantial, with more than 40 million people in the United States infected with T. gondii. Among people infected after birth, fewer than 2% develop ocular lesions, while retinal lesions may occur in 20–80% of congenitally infected individuals by adulthood. Historical U.S. estimates indicate approximately 400–4,000 congenital toxoplasmosis cases annually, while a global systematic review estimated around 190,100 congenital cases per year, equivalent to approximately 1.5 cases per 1,000 live births. Maternal and ocular disease further expand the treatment population, with a meta-analysis of more than 135,000 pregnant women reporting global T. gondii seroprevalence of approximately 36.6%. Ocular toxoplasmosis has also been estimated to represent around 9% of all uveitis cases and approximately 33% of posterior uveitis cases, reinforcing the clinical base for antiparasitic therapy and specialist ophthalmic treatment. Pyrimethamine remains one of the principal medicines used for active toxoplasmosis and is commonly administered with sulfadiazine. Leucovorin, or folinic acid, is routinely added to reduce the risk of pyrimethamine-associated bone marrow toxicity. Other treatment options include trimethoprim-sulfamethoxazole, clindamycin, atovaquone, and azithromycin. Spiramycin is used in selected pregnant patients, particularly where maternal infection is identified before confirmed fetal transmission. Overall, the toxoplasmosis treatment market is supported by a large global infection pool, persistent congenital and ocular disease burden, and continued treatment needs among pregnant and immunocompromised patients. Growth will remain tied to earlier diagnosis, prenatal screening, and sustained use of established antiparasitic combinations such as pyrimethamine with sulfadiazine and leucovorin. Key Takeways: Treatment Mix, Access Channels, and Regional Revenue Hotspots By Disease Type Acquired Toxoplasmosis accounts for a 72% share, representing USD 486.34 million in 2025 revenue, and is projected to expand at a CAGR of 3.90% during 2026–2032. The segment includes acute acquired toxoplasmosis and chronic/latent acquired toxoplasmosis and maintains the largest treatment base due to widespread foodborne and environmental exposure. Congenital Toxoplasmosis holds a 28% share, equivalent to USD 189.13 million in 2025 revenue, and is projected to record the fastest CAGR of 6.12% during 2026–2032. Major subsegments include ocular toxoplasmosis, intracranial manifestations, and systemic neonatal infection, with growth supported by prenatal screening and early diagnosis. By Drug Class Pyrimethamine holds the largest 29% share, generating USD 195.89 million in 2025 revenue, and is projected to grow at a CAGR of 4.20% during 2026–2032. Sulfadiazine represents a 24% share, equivalent to USD 162.11 million in 2025 revenue, and is expected to expand at a CAGR of 3.80% during 2026–2032. Spiramycin accounts for an 18% share, corresponding to USD 121.58 million in 2025 revenue, and is projected to grow at a CAGR of 5.30% during 2026–2032, supported by its role in selected maternal toxoplasmosis cases. Leucovorin/Folic Acid holds a 12% share, representing USD 81.06 million in 2025 revenue, and is expected to expand at a CAGR of 4.40% during 2026–2032. Alternative and Other Agents, including clindamycin, atovaquone, azithromycin, and trimethoprim-sulfamethoxazole, account for a 17% share, generating USD 114.83 million in 2025 revenue, and are projected to record the fastest CAGR of 5.45% during 2026–2032. By Route of Administration Oral Administration dominates with an 81% share, representing USD 547.13 million in 2025 revenue, and is projected to expand at a CAGR of 4.25% during 2026–2032. Tablets and capsules form the principal subsegments because most toxoplasmosis drug regimens are administered orally. Parenteral Administration holds a 19% share, equivalent to USD 128.34 million in 2025 revenue, and is projected to record the fastest CAGR of 5.77% during 2026–2032. The segment includes intravenous and intramuscular formulations used mainly in severe or hospitalized cases. By Distribution Channel Hospital Pharmacies hold the largest 51% share, generating USD 344.49 million in 2025 revenue, and are projected to expand at a CAGR of 4.10% during 2026–2032, supported by treatment of severe ocular, congenital, neurological, and immunocompromised cases. Retail Pharmacies and Drug Stores account for a 34% share, equivalent to USD 229.66 million in 2025 revenue, and are expected to grow at a CAGR of 4.30% during 2026–2032. Online Providers/E-commerce Pharmacies represent a 15% share, corresponding to USD 101.32 million in 2025 revenue, and are projected to record the fastest CAGR of 6.51% during 2026–2032 as digital prescription fulfillment and home delivery expand. By Geography North America holds the largest 37% share, representing USD 249.92 million in 2025 revenue, and is projected to expand at a CAGR of 4.00% during 2026–2032. Europe accounts for a 28% share, equivalent to USD 189.13 million in 2025 revenue, and is expected to grow at a CAGR of 4.20% during 2026–2032, supported by established prenatal screening and specialist infectious-disease care. Asia-Pacific represents a 20% share, generating USD 135.09 million in 2025 revenue, and is projected to record the fastest regional CAGR of 5.70% during 2026–2032. Latin America contributes a 10% share, equivalent to USD 67.55 million in 2025 revenue, and is expected to expand at a CAGR of 5.10% during 2026–2032, supported by comparatively high T. gondii exposure in several South American populations. Middle East & Africa accounts for a 5% share, representing approximately USD 33.78 million in 2025 revenue, and is projected to grow at a CAGR of 4.62% during 2026–2032. Revenue Leaders and Emerging Growth Pockets Across the Toxoplasmosis Treatment Market Leading Subsegments Acquired Toxoplasmosis Leads by Disease Type Acquired toxoplasmosis dominates the Toxoplasmosis Treatment Market with a 72% share, generating USD 486.34 million in 2025, and is projected to expand at a CAGR of 3.90% during 2026–2032. Treatment demand is concentrated among symptomatic patients and those with ocular or CNS involvement, particularly immunocompromised individuals. Standard therapy relies on pyrimethamine with sulfadiazine and leucovorin, while clindamycin and trimethoprim-sulfamethoxazole provide alternatives. Current therapies primarily eliminate active tachyzoites rather than latent tissue cysts, sustaining demand for improved antiparasitic treatments. Pyrimethamine Remains the Core Drug-Class Revenue Contributor Pyrimethamine represented an estimated 29% of the Toxoplasmosis Treatment Market in 2025, generating approximately USD 195.89 million in revenue, and is projected to expand at a CAGR of 4.20% through 2032. Its strong market position reflects its established role as a first-line component of combination therapy for active toxoplasmosis. By inhibiting dihydrofolate reductase, pyrimethamine disrupts parasite folate metabolism and is commonly combined with sulfadiazine and folinic acid for toxoplasmic encephalitis, ocular toxoplasmosis, and congenital toxoplasmosis treatment. Oral Therapy Controls the Route-of-Administration Mix Oral administration dominates the Toxoplasmosis Treatment Market with an 81% share, generating USD 547.13 million in 2025 revenue, and is projected to expand at a CAGR of 4.25% during 2026–2032. It remains the standard route for treating systemic, cerebral, ocular, and congenital toxoplasmosis. Widely used therapies such as pyrimethamine, sulfadiazine, clindamycin, and trimethoprim-sulfamethoxazole can be administered orally, supporting prolonged treatment courses and outpatient management. Its established clinical use and suitability for extended regimens sustain the segment’s leading market position. Hospital Pharmacies Lead Treatment Distribution Hospital pharmacies hold the largest 51% share of the Toxoplasmosis Treatment Market, representing approximately USD 344.49 million in 2025 revenue, and are projected to expand at a CAGR of 4.10% during 2026–2032. Their dominance reflects the hospital-based management of severe toxoplasmosis, including cerebral and congenital cases that require pyrimethamine, sulfadiazine, leucovorin, or alternative combination therapies. Hospital pharmacies also manage restricted drug availability, specialized dosing, inventory requirements, and compounded formulations for pediatric and critically ill patients. North America Holds the Largest Regional Revenue Share North America accounts for an estimated 37% of the Toxoplasmosis Treatment Market, generating USD 249.92 million in 2025 revenue, and is projected to expand at a CAGR of 4.00% during 2026–2032. Market demand is supported by established clinical use of pyrimethamine-sulfadiazine with leucovorin as first-line therapy, alongside clindamycin- and TMP-SMX-based alternatives. In gestational toxoplasmosis, spiramycin is used to reduce maternal-fetal transmission risk, supporting continued pharmaceutical demand across the United States and Canada. Fastest-Growing Subsegments Congenital Toxoplasmosis Creates the Fastest Disease-Type Growth Pocket Congenital toxoplasmosis accounts for 28% of the Toxoplasmosis Treatment Market, generating approximately USD 189.13 million in 2025, and is projected to expand at the fastest disease-type CAGR of 6.12% during 2026–2032. Treatment demand is supported by the need to prevent maternal-to-fetal transmission and reduce lifelong neurological and ocular complications. Prenatal management commonly involves spiramycin or pyrimethamine-sulfadiazine therapy, while infected newborns may require a 12-month regimen of pyrimethamine, sulfadiazine, and folinic acid, sustaining prolonged pharmaceutical utilization. Alternative Agents Are the Fastest-Growing Drug-Class Segment Alternative and other agents account for 17% of the Toxoplasmosis Treatment Market, representing USD 114.83 million in 2025 revenue, and are projected to record the fastest drug-class CAGR of 5.45% through 2032. Growth is supported by the use of TMP-SMX, clindamycin, spiramycin, atovaquone, and azithromycin when standard pyrimethamine-sulfadiazine therapy is unsuitable because of sulfa allergy, treatment intolerance, toxicity, pregnancy-related considerations, or drug availability constraints. Their use across ocular toxoplasmosis, toxoplasmic encephalitis, and congenital infection expands the commercial role of alternative treatment regimens. Parenteral Therapy Records the Fastest Route-of-Administration Growth Parenteral administration accounts for 19% of the Toxoplasmosis Treatment Market, generating USD 128.34 million in 2025 revenue, and is projected to register the fastest CAGR of 5.77% during 2026–2032. Its market role is concentrated in severe toxoplasmosis cases where oral therapy is not feasible, including toxoplasmic encephalitis, gastrointestinal intolerance, malabsorption, and disseminated infection. Intravenous TMP-SMX and clindamycin provide critical acute-care alternatives, although treatment generally transitions to oral regimens once patients stabilize, supporting continued demand across hospitals and immunocompromised patient care. Online Pharmacies Emerge as the Fastest-Growing Distribution Channel Online providers and e-commerce pharmacies account for 15% of the Toxoplasmosis Treatment Market in 2025, generating approximately USD 101.32 million, and are projected to register the fastest distribution-channel CAGR of 6.51% during 2026–2032. Their growth is supported by online access to essential toxoplasmosis medicines such as pyrimethamine, sulfadiazine, and leucovorin. Home-delivery services improve medication availability for patients requiring prolonged treatment, particularly those in remote locations or with mobility limitations, while supporting treatment continuity and adherence. Asia-Pacific Emerges as the Fastest-Growing Regional Market Asia-Pacific accounts for an estimated 20% of the global toxoplasmosis treatment market, generating approximately USD 135.09 million in 2025 revenue, and is projected to record the fastest regional CAGR of 5.70% during 2026–2032. Market growth is supported by improving access to diagnosis and treatment, greater clinical attention to opportunistic infections, and evolving regional treatment practices. Although Toxoplasma gondii seroprevalence remains comparatively lower in parts of Southeast Asia and the Western Pacific, selective screening of high-risk and immunocompromised populations continues to support treatment demand. Competitive Landscape — Established Therapy Brands and Generic Supply GlaxoSmithKline (GSK) GlaxoSmithKline (GSK) stands out among the listed companies because of its direct commercial presence in a cornerstone toxoplasmosis therapy through Daraprim (pyrimethamine). GSK UK's current product information lists Daraprim 25 mg tablets for the treatment of toxoplasmosis, including ocular infection, proven fetal infection following maternal infection, and toxoplasmosis in immunodeficient patients. The therapy is administered with a synergistic agent such as sulfadiazine and folinic acid to reduce pyrimethamine-associated bone-marrow toxicity. Treatment is generally given for 3–6 weeks and for at least six weeks in immunosuppressed patients, giving the product relevance across several high-value patient groups. GSK also provides substantial global pharmaceutical scale behind this established therapy. In 2025, the company reported £32.7 billion in group turnover, invested £6.6 billion in R&D, and supplied more than 2 billion packs of medicines and vaccine doses worldwide. Its combination of an established pyrimethamine brand, infectious-disease capabilities, and large commercial infrastructure gives GSK one of the clearest direct positions in the toxoplasmosis treatment landscape. Other Companies and Their Market Roles Cerovene Inc. — Strengthened U.S. pyrimethamine competition after receiving FDA approval in February 2020 for the first generic Daraprim, pyrimethamine 25 mg, specifically indicated for toxoplasmosis when used with a sulfonamide. Sun Pharmaceutical Industries Ltd. — Supplies oral sulfamethoxazole/trimethoprim in 400/80 mg and 800/160 mg strengths in the U.S.; CDC recognizes TMP-SMX as an alternative toxoplasmosis regimen, giving Sun a role in alternative therapy supply. Teva Pharmaceutical Industries Ltd. — Participates through intravenous sulfamethoxazole/trimethoprim, with current U.S. products containing 80 mg/mL sulfamethoxazole and 16 mg/mL trimethoprim, relevant to the alternative-treatment and hospital channel. Sanofi SA — Has contributed to clinical evidence around spiramycin for maternal toxoplasmosis; a Sanofi-associated meta-analysis included 33 studies, 15,406 mothers, and 15,250 offspring, reinforcing spiramycin's role in reducing congenital transmission. Dr. Reddy’s Laboratories Ltd. — Maintains a broad generic anti-infective presence, including U.S.-listed trimethoprim tablets; its toxoplasmosis exposure is more indirect because clinical guidance generally uses trimethoprim together with sulfamethoxazole rather than trimethoprim alone. Analyst Commentary: Earlier Diagnosis and Safer Regimens Shape the Next Growth Phase The toxoplasmosis treatment market is moving toward earlier diagnosis, risk-stratified therapy, and stronger management of congenital and immunocompromised cases rather than relying only on treatment after symptomatic disease appears. The strongest commercial opportunities are emerging around improved prenatal screening, faster molecular diagnostics, safer alternatives to conventional pyrimethamine-based combinations, and therapies that can reduce toxicity during prolonged treatment. Toxoplasmosis Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 675.47 Million Revenue Forecast in 2032 USD 922.30 Million Overall Growth Rate CAGR of 4.55% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Disease Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography By Disease Type Acquired Toxoplasmosis (acute acquired toxoplasmosis and chronic/latent acquired toxoplasmosis), Congenital Toxoplasmosis (ocular toxoplasmosis, intracranial manifestations, and systemic neonatal infection) By Drug Class Pyrimethamine, Sulfadiazine, Spiramycin, Leucovorin/Folic Acid, Alternative and Other Agents (clindamycin, atovaquone, azithromycin, and trimethoprim-sulfamethoxazole) By Route of Administration Oral Administration (Tablets and capsules), Parenteral Administration (intravenous and intramuscular formulations) By Distribution Channel Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Providers/E-commerce Pharmacies By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Growth will remain tied to earlier diagnosis, prenatal screening, and sustained use of established antiparasitic combinations such as pyrimethamine with sulfadiazine and leucovorin. Customization Option Available upon request Frequently Asked Question About This Report Q1: What factors are creating new opportunities in the market? A1: New opportunities are emerging from prenatal screening, earlier diagnosis, and better management of congenital and ocular infections. Demand is also growing for safer alternatives when conventional pyrimethamine and sulfadiazine combinations are unsuitable. Q2: How are treatment practices changing across the industry? A2: Treatment is becoming more risk-based, with greater attention to pregnant women, newborns, immunocompromised patients, and people with ocular disease. Alternative regimens such as TMP-SMX and clindamycin are also gaining importance in selected cases. Q3: Why is congenital disease becoming an important growth area in the market? A3: Congenital disease is gaining importance because prenatal diagnosis and maternal screening can identify infections earlier. Long treatment courses for infected newborns also create sustained demand for pyrimethamine, sulfadiazine, folinic acid, and related therapies. Q4: What factors are supporting regional expansion in the industry? A4: Regional growth is supported by better diagnostic access, wider screening of high-risk populations, and stronger infectious-disease care. Asia-Pacific is projected to grow fastest as diagnosis and treatment access improve across major healthcare systems. Q5: What could shape future development of the market? A5: Future development will depend on safer long-term therapies, improved prenatal screening, faster diagnostics, and treatments that can better address toxicity and persistent infection. Expanding access to essential antiparasitic medicines will also remain important. Sources: CDC – Toxoplasmosis Overview: More Than 40 Million People Infected in the U.S. CDC Toxoplasmosis Overview CDC – Toxoplasmosis Treatment: Pyrimethamine, Sulfadiazine, Leucovorin, Spiramycin and Alternative Regimens CDC Clinical Care of Toxoplasmosis WHO/PubMed – Global Congenital Toxoplasmosis Burden: Approximately 190,100 Cases Annually PubMed Global Congenital Toxoplasmosis Study U.S. FDA – First Generic Daraprim (Pyrimethamine 25 mg) Approved for Toxoplasmosis FDA First Generic Pyrimethamine Approval U.S. FDA – Daraprim Prescribing Information: Pyrimethamine With Sulfonamide for Toxoplasmosis FDA Daraprim Prescribing Information GSK – Daraprim 25 mg Product Information GSKPro Daraprim Product Information GSK – 2025 Company Performance: £32.7 Billion Turnover and £6.6 Billion R&D Investment GSK 2025 Company Performance CDC – Treatment of Pregnant Women, Ocular Disease and Immunocompromised Patients CDC Toxoplasmosis Treatment Guidance Table of Contents - Global Toxoplasmosis Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Disease Type, Drug Class, Route of Administration, Distribution Channel, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Disease Type, Drug Class, Route of Administration, Distribution Channel, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Disease Type, Drug Class, Route of Administration, and Distribution Channel Investment Opportunities in the Toxoplasmosis Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Congenital Toxoplasmosis, Ocular Toxoplasmosis, Immunocompromised Patient Treatment, Prenatal Management, Alternative Therapies, and Digital Prescription Fulfillment Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Toxoplasmosis Treatment in Congenital, Ocular, Severe, and Immunocompromised Disease Management Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Diagnostic, Prenatal Screening, Treatment Access, and Drug Safety Factors Role of Pyrimethamine, Sulfadiazine, Spiramycin, Leucovorin/Folic Acid, and Alternative Agents in Market Expansion Earlier Diagnosis, Safer Regimens, Treatment Continuity, and Access Management Trends in Toxoplasmosis Care Global Toxoplasmosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type: Acquired Toxoplasmosis Acute Acquired Toxoplasmosis Chronic/Latent Acquired Toxoplasmosis Congenital Toxoplasmosis Ocular Toxoplasmosis Intracranial Manifestations Systemic Neonatal Infection Market Analysis by Drug Class: Pyrimethamine Sulfadiazine Spiramycin Leucovorin/Folic Acid Alternative and Other Agents Clindamycin Atovaquone Azithromycin Trimethoprim-Sulfamethoxazole Market Analysis by Route of Administration: Oral Administration Tablets and Capsules Parenteral Administration Intravenous Formulations Intramuscular Formulations Market Analysis by Distribution Channel: Hospital Pharmacies Retail Pharmacies and Drug Stores Online Providers/E-commerce Pharmacies Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Toxoplasmosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: United States Canada Mexico Europe Toxoplasmosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Toxoplasmosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Toxoplasmosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: Brazil Rest of Latin America Middle East & Africa Toxoplasmosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: GlaxoSmithKline (GSK) Cerovene Inc. Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Sanofi SA Dr. Reddy’s Laboratories Ltd. Viatris Inc. Cipla Limited Aurobindo Pharma Limited Hikma Pharmaceuticals PLC Competitive Landscape and Strategic Insights Benchmarking Based on Product Portfolio, Generic Supply Capability, Infectious Disease Expertise, Distribution Network, Regulatory Reach, and Regional Presence Therapeutic Access and Supply Continuity Analysis Pyrimethamine-Based Therapy Positioning Congenital and Ocular Toxoplasmosis Treatment Competitiveness Alternative Therapy and Immunocompromised Patient Treatment Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Disease Type, Drug Class, Route of Administration, Distribution Channel, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Therapeutic Access, Treatment Availability, and Supply Risk Analysis Treatment Adoption Trends Across Oral Administration, Parenteral Administration, Hospital Pharmacies, Retail Pharmacies and Drug Stores, and Online Providers/E-commerce Pharmacies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Disease Type, Drug Class, Route of Administration, and Distribution Channel (2025 vs. 2032) Global Toxoplasmosis Treatment Ecosystem and Value Chain Analysis